Insulinoma
Rare pancreatic beta-cell neuroendocrine tumor producing endogenous hyperinsulinemic hypoglycemia.
Also known as: insulinoma, pancreatic insulinoma, endogenous hyperinsulinemia, Whipple triad
Overview
Functional pancreatic neuroendocrine tumor (pNET) arising from beta cells that secretes insulin autonomously, causing fasting or postprandial hyperinsulinemic hypoglycemia. Approximately 90% are benign, solitary, and intrapancreatic; 10% are malignant and ~5-10% occur as part of MEN1.
Epidemiology
Annual incidence approximately 1-4 per 1,000,000 person-years. Median age at diagnosis 50; slight female predominance. Most are small (<2 cm) and distributed evenly across the head, body, and tail of the pancreas.
Keep reading — start your free trial
You've read your 2 free diagnosis previews. Create your free account to unlock the full Insulinoma outline — plus all 514 diagnoses, 5,500+ board-style questions, flashcards, and an AI tutor. Your 7-day free trial includes everything, and there's no credit card required.
Risk factors
- MEN1 syndrome — insulinomas in MEN1 are more often multifocal and recur
- Family history of pancreatic neuroendocrine tumors or multiple endocrine neoplasia
- No identified environmental risk factors
Pathophysiology
Autonomous insulin secretion by tumor beta cells is not suppressed by hypoglycemia. C-peptide and proinsulin are co-secreted in molar amounts mirroring insulin synthesis, distinguishing endogenous hyperinsulinemia from exogenous insulin administration (in which insulin is elevated but C-peptide is suppressed). Chronic hypoglycemia leads to hypoglycemia unawareness through downregulation of counterregulatory responses.
Clinical presentation
Symptoms
- Neuroglycopenic: confusion, behavioral change, blurred vision, seizures, loss of consciousness, focal neurologic deficits that may mimic stroke
- Autonomic (often blunted due to hypoglycemia unawareness in chronic disease): tremor, palpitations, sweating, hunger, anxiety
- Symptoms classically occur after fasting (overnight, before breakfast) or after exertion, and resolve with carbohydrate intake
- Weight gain from frequent eating to prevent symptoms
Signs / physical exam
- Often no exam findings between episodes
- During hypoglycemia: diaphoresis, tachycardia, altered mental status, focal deficits
- Look for MEN1 stigmata: multiple lipomas, angiofibromas, parathyroid or pituitary disease
Classic findings
Whipple triad: (1) symptoms consistent with hypoglycemia, (2) measured plasma glucose <55 mg/dL during symptoms, (3) relief of symptoms after glucose administration.
Differential diagnosis
- Exogenous insulin administration (factitious or surreptitious) — Insulin elevated but C-peptide suppressed; consider Munchausen, access to insulin (healthcare worker, diabetic in family)
- Sulfonylurea or meglitinide use (factitious or inadvertent) — Elevated insulin and C-peptide indistinguishable from insulinoma at first; sulfonylurea/meglitinide screen positive in urine or plasma
- Non-islet cell tumor hypoglycemia — Large mesenchymal or epithelial tumor secreting IGF-2 (or 'big IGF-2'); low insulin, low C-peptide, low IGF-1, low IGF-binding proteins; suppressed beta-hydroxybutyrate
- Adrenal insufficiency — Hypoglycemia with hyponatremia, hypotension, fatigue; low cortisol; cosyntropin stimulation
- Severe liver disease or sepsis — Hepatic dysfunction or systemic illness with low insulin and C-peptide; clinical context
- Postprandial (reactive) hypoglycemia — Symptoms 2-5 hours postprandially, no fasting hypoglycemia, normal 72-hour fast; consider post-bariatric surgery
- Nesidioblastosis (noninsulinoma pancreatogenous hypoglycemia) — Diffuse beta-cell hyperplasia; postprandial hypoglycemia after gastric bypass; selective arterial calcium stimulation test localizes to pancreas without discrete tumor
- Insulin autoimmune syndrome (Hirata disease) — High insulin levels with insulin antibodies, more common in East Asian populations or after sulfhydryl-containing drugs (methimazole)
Diagnostic workup
Diagnostic criteria
Whipple triad combined with biochemistry showing inappropriate endogenous hyperinsulinemia (elevated insulin, C-peptide, and proinsulin with suppressed beta-hydroxybutyrate) during documented hypoglycemia, after exclusion of sulfonylurea ingestion. Tumor localization completes the workup.
Labs
- 72-hour supervised fast — gold standard; obtain plasma glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and sulfonylurea/meglitinide screen when glucose falls <55 mg/dL or symptoms develop
- Diagnostic biochemistry during hypoglycemia: insulin ≥3 microU/mL, C-peptide ≥0.6 ng/mL, proinsulin ≥5 pmol/L, beta-hydroxybutyrate ≤2.7 mmol/L, negative sulfonylurea/meglitinide screen, appropriate glycemic response to 1 mg IV glucagon (rise ≥25 mg/dL)
- Calcium, intact PTH, prolactin, IGF-1 if MEN1 suspected
- Insulin antibodies if Hirata disease considered
Imaging
- Contrast-enhanced (arterial-phase) CT or MRI of the pancreas — sensitivity ~70-80% for tumors ≥1 cm
- Endoscopic ultrasound — particularly sensitive for small (<1 cm) intrapancreatic lesions and offers fine-needle aspiration
- 68Ga-DOTATATE PET/CT — useful for somatostatin-receptor-expressing tumors, particularly to evaluate for metastatic disease
- Selective arterial calcium stimulation with hepatic venous sampling — reserved for biochemically confirmed insulinoma with non-localizing imaging or for differentiating insulinoma from nesidioblastosis
- Intraoperative ultrasound and palpation — extremely high sensitivity when used together at experienced centers
Diagnostic algorithm
| Cause of Hypoglycemia | Insulin | C-peptide | Proinsulin | Beta-hydroxybutyrate | Sulfonylurea screen |
|---|---|---|---|---|---|
| Insulinoma | High | High | High | Low | Negative |
| Exogenous insulin (factitious) | High | Low (suppressed) | Low | Low | Negative |
| Sulfonylurea/meglitinide use | High | High | High | Low | POSITIVE |
| Non-islet cell tumor (IGF-2) | Low | Low | Low | Low | Negative |
| Adrenal insufficiency / sepsis / liver | Low | Low | Low | High | Negative |
Treatment
First-line
- Surgical resection — enucleation for small, peripheral tumors; distal pancreatectomy or pancreaticoduodenectomy (Whipple) for larger, deep, or malignant lesions
- Intraoperative ultrasound and palpation to confirm location and exclude additional lesions, particularly in MEN1
- Frequent small meals with complex carbohydrates as a temporizing measure
Second-line / adjunct
- Diazoxide — opens beta-cell K-ATP channels to inhibit insulin secretion; useful for unresectable, metastatic, or non-localized insulinoma; side effects include sodium retention, edema, and hirsutism
- Somatostatin analog — octreotide, lanreotide — can paradoxically worsen hypoglycemia by suppressing counterregulatory glucagon if tumor expresses somatostatin receptor 5 disproportionately; test response carefully
- Everolimus (mTOR inhibitor) — improves glycemic control in advanced metastatic insulinoma
- Peptide receptor radionuclide therapy (177Lu-DOTATATE) for progressive metastatic disease with positive somatostatin receptor imaging
- Hepatic artery embolization, radiofrequency ablation, or chemotherapy (streptozocin-based regimens) for hepatic metastases
Complications
- Recurrent severe hypoglycemia with neuroglycopenia, seizures, motor vehicle accidents, fall injuries
- Long-term neurocognitive impairment from repeated severe hypoglycemia
- Hypoglycemia unawareness
- Postoperative complications: pancreatic fistula, pseudocyst, diabetes mellitus (after extensive resection or in MEN1)
- Metastatic disease in malignant insulinoma (~10% of cases) — most commonly to liver
PANCE pearls
- Whipple triad plus inappropriate endogenous hyperinsulinemia (elevated insulin, C-peptide, AND proinsulin during hypoglycemia, with negative sulfonylurea screen) confirms insulinoma — C-peptide is the key distinguishing test against exogenous insulin administration.
- Always send a sulfonylurea and meglitinide screen during the 72-hour fast — surreptitious oral hypoglycemic use perfectly mimics insulinoma biochemistry and is a tragic missed diagnosis if not excluded.
- Insulinomas in MEN1 are typically multiple and recurrent — preoperative imaging strategy and surgical approach (often distal pancreatectomy with enucleation of head lesions) differ from sporadic disease.
- Diazoxide can cause prominent sodium retention and edema — co-administer a thiazide diuretic to potentiate its hyperglycemic effect and counter fluid retention.
- Most insulinomas are small (<2 cm) and within the pancreas, so a normal abdominal CT does not exclude the diagnosis — endoscopic ultrasound and selective arterial calcium stimulation are sensitive localizing tools.
References
- Endocrine Society 2009 — Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline (Cryer et al., J Clin Endocrinol Metab 2009)
- NANETS 2013 — North American Neuroendocrine Tumor Society Consensus Guidelines for the Diagnosis of Neuroendocrine Tumor: Pancreatic NETs (Kulke et al., Pancreas 2013)
- ENETS 2016 — ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors (Falconi et al., Neuroendocrinology 2016)
- Endocrine Society 2012 — Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (Thakker et al., J Clin Endocrinol Metab 2012)
Practice Endocrinology questions on FirstPassPA
Turn this outline into retention. 5,500+ board-style questions with an AI tutor that explains every answer — free to start, no card required.
Start studying free → Browse all 514 diagnosesEducational use only. This outline is a study aid for PA students and is not medical advice or a substitute for clinical judgment. FirstPassPA is an independent study tool and is not affiliated with, endorsed by, or sponsored by NCCPA or PAEA. PANCE® and PANRE® are registered trademarks of the National Commission on Certification of Physician Assistants; End of Rotation™ is a program of the Physician Assistant Education Association.